Document Detail


Nerve growth factor level in the prostatic fluid of patients with chronic prostatitis/chronic pelvic pain syndrome is correlated with symptom severity and response to treatment.
MedLine Citation:
PMID:  20883485     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
OBJECTIVE: •  To explore whether levels of nerve growth factor (NGF) in expressed prostatic secretions (EPS) are correlated with symptom severity in chronic prostatitis (CP) and chronic pelvic pain syndrome (CPPS).
PATIENTS AND METHODS: •  All patients with CP/CPPS underwent a complete history and physical examination, and were scored according to the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). •  Expressed prostatic secretion samples from 20 patients with CP/CPPS and from four asymptomatic control patients were collected and frozen, and NGF levels in EPS were measured by enzyme-linked immunosorbent assay. •  Patients were asked to complete NIH-CPSI questionnaires at baseline and 8 weeks after treatment and patients with at least a 25% decrease in total NIH-CPSI score from the baseline values were classified as responders to treatment.
RESULTS: •  The mean (±sd) NGF levels in EPS of patients with CP/CPPS and asymptomatic control patients were 7409 (±3788) pg/mL and 4174 (±1349) pg/mL, respectively. The NGF level in patients with CP/CPPS correlated directly with pain severity (P= 0.014, r= 0.541). •  There were no significant differences between NGF levels in EPS before and after treatment. However, successful treatment significantly decreased NGF levels in responders (P= 0.001).
CONCLUSION: •  Nerve growth factor might contribute to the pathophysiology of CP/CPPS as changes in NGF level in EPS occurred in proportion to pain severity. Therefore, these results suggest that NGF could be used as a new biomarker to evaluate the symptoms of CP/CPPS and the effects of treatment.
Authors:
Toyohiko Watanabe; Miayabi Inoue; Katsumi Sasaki; Motoo Araki; Shinya Uehara; Koichi Monden; Takashi Saika; Yasutomo Nasu; Hiromi Kumon; Michael B Chancellor
Related Documents :
3383945 - High-dose ketoconazole to untreated stage d prostate cancer.
18371475 - Prognostic importance of creatine kinase and creatine kinase-mb after primary percutane...
19762705 - Patients with alzheimer disease with multiple microbleeds: relation with cerebrospinal ...
12408465 - Prostate-specific antigen levels among cirrhotic patients.
11929485 - Increased release of matrix metalloproteinase-9 in the plasma of acute severe asthmatic...
24608275 - Low radioiodine uptake in congestive heart failure.
Publication Detail:
Type:  Journal Article     Date:  2010-09-30
Journal Detail:
Title:  BJU international     Volume:  108     ISSN:  1464-410X     ISO Abbreviation:  BJU Int.     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-07-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100886721     Medline TA:  BJU Int     Country:  England    
Other Details:
Languages:  eng     Pagination:  248-51     Citation Subset:  IM    
Copyright Information:
© 2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.
Affiliation:
Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, and Department of Neurourology, Beaumont Hospital, Royal Oak, MI, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperp...
Next Document:  Lymphatic vessel density as a predictor of lymph node metastasis and its relationship with prognosis...